Compugen (NASDAQ:CGEN) Stock Passes Above Two Hundred Day Moving Average – Should You Sell?

Compugen Ltd. (NASDAQ:CGEN)’s share price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.50 and traded as high as $1.88. Compugen shares last traded at $1.81, with a volume of 405,295 shares changing hands.

Wall Street Analyst Weigh In

Several research analysts have weighed in on CGEN shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Compugen in a report on Wednesday. Wall Street Zen lowered shares of Compugen from a “hold” rating to a “sell” rating in a research report on Saturday, August 9th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Compugen has an average rating of “Hold” and an average target price of $4.00.

Compugen Price Performance

The firm has a market capitalization of $161.52 million, a PE ratio of -8.23 and a beta of 2.61. The firm’s fifty day moving average is $1.47 and its two-hundred day moving average is $1.50.

Compugen (NASDAQ:CGEN) last released its earnings results on Wednesday, August 6th. The biotechnology company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). The company had revenue of $1.26 million during the quarter, compared to analysts’ expectations of $3.95 million. Compugen had a negative net margin of 87.45% and a negative return on equity of 34.77%. As a group, equities research analysts predict that Compugen Ltd. will post -0.03 EPS for the current fiscal year.

Institutional Investors Weigh In On Compugen

Several institutional investors have recently added to or reduced their stakes in the company. US Bancorp DE purchased a new stake in shares of Compugen in the 1st quarter worth about $29,000. ARK Investment Management LLC purchased a new stake in shares of Compugen in the 1st quarter worth about $1,323,000. Calamos Wealth Management LLC purchased a new stake in shares of Compugen in the 1st quarter worth about $43,000. Schnieders Capital Management LLC purchased a new stake in shares of Compugen in the 1st quarter worth about $131,000. Finally, Jane Street Group LLC lifted its position in shares of Compugen by 1,077.0% in the 2nd quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company’s stock worth $700,000 after purchasing an additional 359,785 shares during the period. Hedge funds and other institutional investors own 12.22% of the company’s stock.

Compugen Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.